Amerise Biosciences reported a net loss of ₹8.14 lakh for the quarter ended June 30, 2026 (Q1FY27), a significant deterioration from the net profit of ₹6.13 lakh recorded in the preceding quarter. The financial setback was primarily driven by the absence of revenue from product sales and a substantial rise in other operating expenses, which jumped to ₹7.21 lakh from ₹0.34 lakh in Q4FY26. Total income for the quarter stood at nil, as both gross revenue from sale of products and other operating revenue were zero, compared to ₹7.92 lakh in the previous quarter.

The Board of Directors approved the unaudited standalone financial results on August 03, 2026, pursuant to Regulation 33 read with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting commenced at 04:50 PM and concluded at 05:10 PM at the company’s registered office in Ahmedabad. The results have been reviewed by the Audit Committee and subjected to a limited review by the statutory auditors, Bipin & Co., Chartered Accountants.

Financial Performance Breakdown

The company’s total expenses for Q1FY27 amounted to ₹8.14 lakh, comprising employee benefit expenses of ₹0.94 lakh and other expenses of ₹7.21 lakh. In contrast, total expenses in the previous quarter were significantly lower at ₹1.79 lakh. The surge in other expenses outpaced the reduction in employee benefits, which fell to ₹0.94 lakh from ₹1.45 lakh in Q4FY26. No finance costs or depreciation expenses were recorded during the period.

Year-to-date figures for FY26 showed a net profit of ₹1.61 lakh on total income of ₹25.52 lakh. For the comparative quarter ended June 30, 2025 (Q1FY26), the company had reported a net loss of ₹0.81 lakh on total income of ₹6.37 lakh. The current quarter’s performance marks a deeper loss than the same period last year, indicating ongoing operational challenges.

What the Numbers Show

The most critical aspect of Amerise Biosciences’ Q1FY27 results is the complete cessation of revenue generation. With both gross revenue and other operating revenue at nil, the company incurred costs without any offsetting inflows. The spike in 'other expenses' to ₹7.21 lakh suggests potential one-time charges or increased administrative overheads that were not present in the prior quarter. This divergence between zero revenue and rising non-employee expenses highlights a period of operational dormancy or transition, where fixed costs continue to accrue while business activity remains stalled. The paid-up equity share capital remained unchanged at ₹660.69 lakh.

Amerise Biosciences Ltd disclosed that Snehjeev Ventures Pvt Ltd, along with its persons acting in concert (PACs), crossed the 9% shareholding threshold in the company on July 20, 2026. This development triggers a mandatory disclosure under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The crossing of this regulatory threshold is significant as it marks a substantial increase in outside investor concentration in the Ahmedabad-based biosciences firm.

The acquirer, Snehjeev Ventures Pvt Ltd, acquired 28,000 equity shares through open market transactions. This purchase pushed the group’s aggregate holding from 8.98% to 9.02% of the total voting capital. Prior to this specific acquisition, the group held 5,934,355 shares. Following the addition of the new shares, the total holding stands at 5,962,355 shares. There were no encumbrances, pledges, or liens associated with these acquired securities, nor were there any warrants or convertible instruments involved in the transaction.

The persons acting in concert with Snehjeev Ventures include Rushank SS Lunkad, Sneha Lunkad, Riddhi Lunkad, and Sanjeev Lunkad. Rushank SS Lunkad, a director at Snehjeev Ventures, signed the disclosure document dated July 21, 2026. The disclosure confirms that the acquirer does not belong to the promoter or promoter group of Amerise Biosciences Ltd. The entire holding consists of ordinary equity shares carrying voting rights.

Amerise Biosciences Ltd has an authorized equity share capital structure consisting of 66,06,900 equity shares with a face value of ₹10 each, totaling ₹6,60,69,000. The total diluted share/voting capital remains unaffected by this transaction as no convertible securities were exercised. The company submitted these disclosures to the BSE Limited listing department on July 29, 2026, as required by regulatory norms for substantial acquisitions.

Acquisition Details

What the Numbers Show

The precise nature of the acquisition highlights a strategic accumulation of stake just above the 9% regulatory reporting line. The group moved from 8.98% to 9.02%, indicating that the 28,000-share purchase was likely calculated to trigger or slightly exceed this specific disclosure mandate rather than a bulk block deal. With no encumbrances on the shares, the holding represents clean equity exposure. The fact that the acquirer is not part of the promoter group suggests this is an independent investment move, potentially signaling confidence in the company’s operational trajectory or valuation levels at the time of purchase.